SAN DIEGO--(BUSINESS WIRE)--Mar. 13, 2017--
Heron Therapeutics, Inc. (NASDAQ: HRTX), a commercial-stage
biotechnology company focused on developing novel best-in-class
treatment solutions to address some of the biggest unmet patient needs,
announced that Barry D. Quart, Pharm.D., Chief Executive Officer of
Heron Therapeutics, will present at the Oppenheimer 27th
Annual Healthcare Conference on Tuesday, March 21, 2017, at 10:55 a.m.
ET (7:55 a.m. PT) at the Westin Grand Central Hotel in New York.
A live webcast of this presentation and accompanying slides will be
available on the Company’s website at www.herontx.com
in the Investor Resources section. A replay of the presentation will be
archived on the site for 60 days.
About Heron Therapeutics, Inc.
Heron Therapeutics, Inc. is a commercial-stage biotechnology company
focused on improving the lives of patients by developing best-in-class
medicines that address major unmet medical needs. Heron is developing
novel, patient-focused solutions that apply its innovative science and
technologies to already-approved pharmacological agents for patients
suffering from cancer or pain. For more information, visit www.herontx.com.
This news release contains "forward-looking statements" as defined by
the Private Securities Litigation Reform Act of 1995. Heron cautions
readers that forward-looking statements are based on management’s
expectations and assumptions as of the date of this news release and are
subject to certain risks and uncertainties that could cause actual
results to differ materially. These risks and uncertainties include, but
are not limited to, risks and uncertainties identified in the Company's
filings with the Securities and Exchange Commission. Forward-looking
statements reflect our analysis only on their stated date, and Heron
takes no obligation to update or revise these statements except as may
be required by law.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170313006268/en/
Source: Heron Therapeutics, Inc.
Investor Relations and Media Contact:
David Szekeres, 858-251-4447
General Counsel, Business Development and Corporate Secretary